毒品史研究的新成果——读肖红松近著《近代河北烟毒与治理研究》

《近代河北烟毒与治理研究》是毒品史研究的新成果,不仅标志着近代河北毒品与治理研究的突破性进展,而且对其他区域及当前的毒品与治理研究均有借鉴和启示意义。     

网上招生数据标准化接口系统的设计与实现

高校招生数据的发布是高校招生工作及学校教学管理工作的一项基础性数据准备工作,由于各部门对数据格式要求的不一致,加上手工参与数据处理过程,导致新生数据发布存在一定的混乱及与原始数据的不一致的问题,为此研究并设计一套符合高校招生系统与学校教务系统之间的数据标准化接口软件,来优化数据管理流程,减少手工参与,科学、高效地完成学校基础数据的收集与管理,按各部门需求,自动、灵活导出规定格式数据,最终实现招生数据快速、准确地提供给学校相关职能部门。     

铅球最佳投出角问题新探

为了解决铅球适宜投出角度公式与实践偏离的问题，分析了铅球成绩与抛体最大射程的函数关系，得出了最大成绩定理、“新”最佳投出角度公式和最佳出手角度标志线参数式。抽样检验和空气动力学实验指出，新公式能够准确地描述出高、中、低各种水平铅球运动员的适宜出手角度。     

探析我国药品价格监管之路

本文从国际视角出发,研究了我国药物价格管制的动机与管制失灵的原因．并且发现是管制模式导致了药品价格调控失败而不是由于医药合业的模式带来问题。由于医药分业改革的复杂性和不确定性,本文认为改进管制模式将成为有效控制药品价格最实际可行的途径。     

模仿创新与仿制药的竞争战略

仿制药市场因为较容易进入,药品模仿创新由于成本与风险的降低,都被视为中国制药业的机会。本文通过对仿制药市场结构及药品模仿创新战略的分析,揭示了这两者在看似吸引人的表面背后存在着的挑战与风险。本文首先分析仿制药快速增长的驱动力,并肯定了这种增长趋势的存在。接着,本文分析了仿制药市场的竞争结构,主要是品牌药品的优势与新进入者的威胁。从这种分析出发,本文把模仿创新作为技术战略与竞争战略来讨论其实际途径与战略管理。由此,本文实际上也对模仿创新作为技术战略的成功条件作出了讨论:它必须与营销战略、市场定位相一致才能取得市场优势,而取得市场优势是技术战略成功的前提。     

Drug Delivery of Hydroxyurea to Breast Cancer Using Liposomes

It is clear that cancer is one of the most mortal diseases in the world and the most prevalent among women is breast cancer. As hydroxyurea (HU)—a drug which is used in chemotherapy—has many adverse effects in long-term despite of its therapeutic properties, we made use of nano drug delivery technology in order to reduce adverse effects and increase therapeutic index. Thus, liposomation is a novel way in drug delivery systems. In this study a mixture of phosphatidylcholine and cholesterol was mixed and HU was added to the resultant mixture. The mean diameter of the nanoliposomal HU measured with the Zeta Sizer device (equal to 402.5 nm) and its encapsulation efficiency was 70.8 %. Besides, using dialysis, the pattern of drug release from nanoliposomes has been studied and the results showed that the drug release of nanoliposomal drug within 28 h was equal to 25.85 %. This study showed that the cytotoxicity effect of nanoliposomal drug is more than that of the standard drug.     

公司创业投资者与创业企业家之间的信息困境及进化博弈分析

对公司投资者和创业企业家之间的信息困境进行了分析，在此基础上建立了二者的信息博弈模型，并运用进化博弈理论分析了公司创业投资市场主体的博弈过程和进化稳定策略，讨论了不同强度的知识产权保护环境对博弈的影响。最后，对如何规范市场主体行为提出了建议。     

基于“第二课堂”调研下山东农村家庭安全用药的探究

通过开展第二课堂实践活动,调研了解山东农村家庭安全用药情况并科普,实现专业知识和调研实践的学习与应用。采用整群随机抽样法分别在山东省东、中、西部抽取10个行政村,在随机抽取60户家庭,对山东农村家庭安全用药情况展开调研,同时设计调查问卷进行发放填写。问卷结果显示,不同人群对安全用药知识均存在盲区,且对常见药品和疾病了解甚少。山东农村家庭对安全用药知识和常见疾病掌握较少,针对出现的问题提出科普方案并编写《家庭安全用药手册》。     

大专院校食品药品监督管理专业建设的思考

随着食品安全战略的实施,人们对健康的重视不断加深,市场对食品药品监督管理专业人员的需求量日益增大。本文以遵义医药高等专科学校为例,运用典型调查、深入访谈等方法,选择贵阳、遵义、铜仁等地开展实地调研,探讨了大专院校食品药品监督管理专业的建设定位、培养标准、课程建设、师资要求,为大专院校食品药品监督管理专业建设提供参考。     

US biopharmaceutical finance and the sustainability of the biotech business model

In the decade before the 2008 economic crisis, the US biotechnology industry was booming. In a 2006 book, Science Business: The Promise, the Reality, and the Future of Biotech, Gary Pisano implies that, given the 10-20 year time-frame for developing biotech products and the lack of profitability of the industry as a whole, the US biotech boom should not have happened. Yet the biotech industry has received substantial funding from venture-capital firms as well as from established companies through R&D alliances. Why would money from venture capitalists and big pharma flow into an industry in which profits are so hard to come by? The purpose of this article is to work toward a solution of what might be called the “Pisano puzzle”, and in the process to provide a basis for analyzing the industrial and institutional conditions under which the growth of the US biopharmaceutical (BP) industry is sustainable. One part of the answer has been the willingness of stock-market investors to absorb the initial public offerings (IPOs) of a BP venture that has not yet generated a commercial product, and indeed may never do so. The other part of the answer is that the knowledge base that BP companies can tap to develop products comes much more from government investments and spending than from business finance. Indeed, we show that, through stock buybacks and dividends, established corporations in the BP industry have been distributing substantial sums of cash to shareholders that may be at the expense of R&D. We use the framework that we have developed for analyzing the sustainability of the US BP business model to pose a number of key areas for future research and policy, with an emphasis on the implications of the financialization of this business model for the generation of safe and affordable BP drugs as well as the need for a theory of innovative enterprise.